InvestorsHub Logo
Followers 13
Posts 2213
Boards Moderated 0
Alias Born 08/11/2017

Re: None

Friday, 12/18/2020 8:45:12 AM

Friday, December 18, 2020 8:45:12 AM

Post# of 334
Exicure initiated with an Outperform at BMO Capital

BMO Capital analyst Do Kim initiated coverage of Exicure with an Outperform rating and $6.00 price target. The company's opportunities in neurological diseases are under-appreciated in spite of the compelling validation for oligonucleotides to correct genetic drivers of hereditary central nervous system disorders, the analyst tells investors in a research note. Kim adds that given the lead drug XCUR-FXN's pre-clinical data and the filing in 2021 to support clinical benefit, he sees a "compelling" risk-reward opportunity for Exicure.

Read more at:
https://thefly.com/n.php?id=3215717

MegaDeath, changed due to circumstances of COVID-19 pandemic.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XCUR News